RE-BVS – Piemonte Repository

Sfoglia per AUTORE
PELLA N
Collezione ASL Biella

Items : 14

Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index. in Journal of gastrointestinal cancer / J Gastrointest Cancer. 2022 Jun;53(2):289-298. doi: 10.1007/s12029-021-00596-z. Epub 2021 Feb 5.

2022
ASL Biella
AO Ordine Mauriziano
AOU Città della Salute di Torino

Casadei-Gardini A; Cascinu S; Orsi G; Aprile G; Di Maio M; Jeong JH; de Braud F; Vasile E; De Lorenzo S; Pella N; Fenocchio E; Nichetti F; Lai E; Cho H; Vivaldi C; Aglietta M; Faloppi L; Palloni A; Santini D; Silvestris N; Casagrande M; Filippi R; Scartozzi M; Niger M; Yoo C; Caputo F; Fornaro L; Brandi G; Rovesti G; et alii...

Risk-adjusted analysis of survival variability among hospitals treating biliary malignancy. in Journal of chemotherapy (Florence, Italy) / J Chemother. 2022 Dec;34(8):543-549. doi: 10.1080/1120009X.2022.2036557. Epub 2022 Feb 14.

2022
ASL Biella
AOU Città della Salute di Torino
AO Ordine Mauriziano

Aldrighetti L; Sperti E; Burgio V; Ratti F; Cucchetti A; Cascinu S; Faloppi L; Pellino A; Salani F; Scartozzi M; Vivaldi C; Satolli MA; Fenocchio E; Aprile G; Frega G; Aglietta M; Santini D; Palloni A; Filippi R; Masi G; Galizia E; Silvestris N; Montagnani F; Lonardi S; Lai E; Fornaro L; Pella N; Leone F; Brandi G; et alii...

From CENTRAL to SENTRAL (SErum aNgiogenesis cenTRAL): Circulating Predictive Biomarkers to Anti-VEGFR Therapy. in Cancers / Cancers (Basel). 2020 May 22;12(5):1330. doi: 10.3390/cancers12051330.

2020
ASL Biella

Scartozzi M; Labianca R; Cascinu S; Puzzoni M; Libertini M; Zagonel V; Codecà C; Germano D; Lai E; Sozzi P; Pusceddu V; Zampino MG; Demurtas L; Pella N; Casagrande M; Cavanna L; Rosati G; Zaniboni A; Ferrari D; Lonardi S; Zizzi A; Daniele B; Ziranu P; Giampieri R;

Author Correction: Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy. in Scientific reports / Sci Rep. 2020 Jan 31;10(1):1918. doi: 10.1038/s41598-020-58486-6.

2020
ASL Biella

Sobrero A; Frontini L; Bergamo F; Verusio C; Lazzarelli S; Turci D; Bramati A; Biondi E; Foltran L; Nicolini M; Ricci V; Barni S; Sozzi P; Veltri E; Bagaloni I; Mucciarini C; Labianca R; Ionta MT; Zagonel V; Pella N; Ronzoni M; Massidda B; Lonardi S; Rulli E; Magnani M; Galli F; Graziano F; Galli F; Ruzzo A; et alii...

Khorana score and thromboembolic risk in stage II-III colorectal cancer patients: a post hoc analysis from the adjuvant TOSCA trial. in Therapeutic advances in medical oncology / Ther Adv Med Oncol. 2020 Jan 20;12:1758835919899850. doi: 10.1177/1758835919899850. eCollection 2020

2020
ASL Biella

Galli F; Giordani P; Galli F; Aglietta M; Clerico M; Moroni M; Piazza E; Pavesi L; Silvestris N; Buonadonna A; Ciarlo A; Frassineti GL; De Placido S; Iaffaioli V; Sobrero A; Bidoli P; Zaniboni A; Labianca R; Ferrari D; Artioli F; Maiello E; Marchetti P; Dotti KF; Rimassa L; Zampino MG; Petrelli F; Banzi M; Pella N; Rosati G; et alii...

Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy. in Scientific reports / Sci Rep. 2019 Aug 8;9(1):11527. doi: 10.1038/s41598-019-47627-1.

2019
ASL Biella

Predicting HER2 status in esophagogastric cancer: Development and validation of an easy-to-use nomogram in Annals of Oncology

2018
ASL Biella

Fornaro L; Parnofiello A; Ugolini C; Cardarelli N; De Maglio G; Pecora I; Crivelli F; Catanese S; Cardellino G; Musettini G; Pella N; Pasquini G; Pizzolitto S; Salani F; Clerico M; Fontanini G; Fasola G; Maurizio D; Vivaldi C; Montagnani F;

Predicting HER2 status in esophagogastric cancer: Development and validation of an easy-to-use nomogram in Annals of Oncology

2018
ASL Biella

Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients. in British journal of cancer / Br J Cancer. 2017 Oct 24;117(9):1269-1277. doi: 10.1038/bjc.2017.289. Epub 2017 Aug 24.

2017
ASL Biella

Menghi M; Magnani M; Verusio C; Frontini L; Sobrero A; Bergamo F; Lazzarelli S; Biondi E; Bramati A; Turci D; Nicolini M; Foltran L; Ricci V; Sozzi P; Barni S; Bagaloni I; Veltri E; Ionta MT; Labianca R; Mucciarini C; Ronzoni M; Massidda B; Zagonel V; Pella N; Lonardi S; Galli F; Rulli E; Galli F; Ruzzo A; et alii...

First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial. in British journal of cancer / Br J Cancer. 2017 Oct 10;117(8):1099-1104. doi: 10.1038/bjc.2017.234. Epub 2017 Sep 19.

2017
ASL Biella

Cascinu S; Labianca R; Codecà C; Libertini M; Zagonel V; Sozzi P; Germano D; Zampino MG; Pella N; Rosati G; Cavanna L; Zaniboni A; Lonardi S; Ferrari D; Daniele B; Puzzoni M; Giampieri R; Scartozzi M;

Germline variants and clinical outcomes of high-risk stage II and stage III colon cancer patients treated with oxaliplatin and fluoropyrimidines adjuvant chemotherapy: A pharmacogenetic ancillary study to TOSCA trial in Annals of Oncology

2017
ASL Biella
AO Ordine Mauriziano

Ruzzo A; Galli F; Rulli E; Lonardi S; Zagonel V; Ronzoni M; Ionta MT; Pella N; Mucciarini C; Labianca R; Veltri E; Sozzi P; Barni S; Nicolini M; Biondi E; Bramati A; Turci D; Buscaglia M; Magnani M; Graziano F; Tampellini M; Falco E; De Rosa G; Montarolo F; Dacomo R; Baratelli C; Sperti E; Di Maio M; Scagliotti GV; et alii...

Germline variants and clinical outcomes of high-risk stage II and stage III colon cancer patients treated with oxaliplatin and fluoropyrimidines adjuvant chemotherapy: a pharmacogenetic ancillary study to TOSCA trial in Annals of oncology : official journal of the European Society for Medical Oncology

2017
ASL Biella

First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: Final results of the Italian Research Group for Digestive Tract Cancer (GISCAD) CENTRAL (ColorEctalvastiNTRiAlLdh) and SENTRAL (Serum angiogenesis-cENTRAL) analysis in Journal of Clinical Oncology

2016
ASL Biella

Scartozzi M; Giampieri R; Daniele B; Ferrari D; Lonardi S; Zaniboni A; Cavanna L; Rosati G; Pella N; Zampino MG; Sozzi P; Casula L; Cozzi L; Germano D; Puzzoni M; Loretelli C; Zagonel V; Labianca R; Frontini L; Cascinu S;

Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients. in Scientific reports / Sci Rep. 2014 Nov 5;4:6828. doi: 10.1038/srep06828.

2014
ASL Biella

Magnani M; Frontini L; Lazzarelli S; Verusio C; Bergamo F; Sobrero A; Turci D; Bramati A; Biondi E; Ricci V; Foltran L; Nicolini M; Veltri E; Sozzi P; Barni S; Zagonel V; Pella N; Mucciarini C; Ionta MT; Labianca R; Lonardi S; Ronzoni M; Massidda B; Rulli E; Floriani I; Galli F; Giacomini E; Graziano F; Galli F; et alii...